NK cells with improved ability to target and kill cancer cells and use thereof
iPSC-based NK cells with CXCR4, CCR7, and IL-15/IL-15Rα genes enhance cancer cell targeting and activation, addressing the limitations of existing immunotherapy by improving cancer cell killing efficacy and persistence.
WO2026117036A1PCT designated stage Publication Date: 2026-06-04THERABEST CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/KR2025/019951
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-27
- Filing Date
- 2025-11-27
- Publication Date
- 2026-06-04
AI Technical Summary
Technical Problem
Existing immunotherapy drugs, such as CAR-T cell therapies, have limitations in single treatment efficacy and persistence in the body, failing to effectively target and eliminate cancer cells due to insufficient activation and low persistence.
Method used
Development of iPSC-based NK cells with introduced CXCR4, CCR7, and IL-15/IL-15Rα genes to enhance cancer cell targeting and activation, enabling direct antigen recognition and intracellular signaling for improved cancer cell killing.
Benefits of technology
The transformed NK cells demonstrate enhanced cancer cell targeting and killing ability, activating CD8+ T cells and inducing proliferation, effectively treating various cancer types with reduced side effects and improved persistence.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure KR2025019951_04062026_PF_FP_ABST
Abstract
The present invention relates to NK cells with an improved ability to target and kill cancer cells and use thereof. Specifically, the present invention relates to: iPSC-based NK cells into which a chimeric antigen receptor targeting a specific cancer antigen, CXCR4 and CCR7 genes, which are chemokine receptors, and an IL-15 / IL-15Rα (IL-15RF) gene are introduced; and use thereof for treating cancer. The iPSC-based NK cells according to the present invention can not only directly target a specific cancer antigen by the introduced CAR, but can also activate NK cells and enhance the proliferation thereof by regulating intracellular signaling and tumor microenvironment by the introduced CXCR4 and CCR7 and the introduced IL-15RF. Therefore, the NK cells into which multiple genes are introduced, according to the present invention, can efficiently target and attack cancer cells, and thus can be effectively used for the treatment of cancer diseases.
Need to check novelty before this filing date? Find Prior Art